請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/15577
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 蕭培文 | |
dc.contributor.author | Chi-Han Wu | en |
dc.contributor.author | 吳奇翰 | zh_TW |
dc.date.accessioned | 2021-06-07T17:48:11Z | - |
dc.date.copyright | 2013-04-26 | |
dc.date.issued | 2013 | |
dc.date.submitted | 2013-04-02 | |
dc.identifier.citation | 1. Hanahan D and Weinberg RA : Hallmarks of Cancer: The Next Generation. Cell 144:646-674, 2011.
2. Talmadge JE and Fidler IJ: AACR centennial series: the biology of cancer metastasis: historical perspective. Cancer Res. 70:5649–5669, 2010. 3. Fidler IJ : The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nat. Rev. Cancer 3:453–458, 2003. 4. People Health Bureau of Taiwan: http://www.doh.gov.tw/CHT2006/DisplayStatisticFile.aspx?d=84766&s=1 5. Risbridger GP, Davis ID, Birrell SN, and Tilley WD : Breast and prostate cancer: more similar than different. Nature Rev Cancer 10:205-212, 2010. 6. Asad Umar, Barbara K. Dunn, and Peter Greenwald: Future directions in cancer prevention. Nature Rev Cancer 12:835-848, 2012. 7. De Marzo AM, Meeker AK, Zha S, Luo J, Nakayama M, Platz EA, Isaacs WB, and Nelson WG: Human prostate cancer precursors and pathobiology. Urology 62:55-62,2003. 8. Zhu P, Baek SH, Bourk EM, Ohgi KA, Garcia-Bassets I, Sanjo H, Akira S, Koto PF, Glass CK, Rosenfeld MG , and Rose DW: Macrophage/cancer cell interactions mediate hormone resistance by a nuclear receptor derepression pathway. Cell 124:615–629,2006. 9. Jemal A , Siegel R, Ward E, Hao Y, Xu J, and Thun MJ: Cancer Statistics, 2009. CA Cancer J. Clin. 59:225–249 ,2009. 10. Early Breast Cancer Trialists’ Collaborative Group: Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351: 1451–1467 ,1998. 11. Early Breast Cancer Trialists’ Collaborative Group : Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 352: 930–942 ,1998. 12. Clarke R, Leonessa F, Welch J N ,and Skaar TC: Cellular and molecular pharmacology of antiestrogen action and resistance. Pharmacol. Rev. 53: 25–71 (2001). 13. Baron JA and Sandler RS: Nonsteroidal anti-inflammatory drugs and cancer prevention. Annu. Rev. Med. 51:511–523 (2000) 14. Ho E, Boileau TWM, and Bray TM: Dietary influences on endocrine–inflammatory interactions in prostate cancer development. Arch. Biochem. Biophys., 428:109–117 (2004) 15. Demicheli R, Retsky MW, Hrushesky WJ, Baum M, and Gukas ID : The effects of surgery on tumor growth: a century of investigations. Ann. Oncol. 19:1821–1828, 2008. 16. Barkan D, Green JE, and Chambers AF : Extracellular matrix: a gatekeeper in the transition from dormancy to metastatic growth. Eur. J. Cancer 46:1181–1188, 2010. 17. Aguirre-Ghiso JA: Models, mechanisms and clinical evidence for cancer dormancy. Nat. Rev. Cancer 7: 834–846, 2007. 18. Townson JL and Chambers AF: Dormancy of solitary metastatic cells. Cell Cycle 5:1744–1750, 2006. 19. Chiang LC, Chang JS, Chen CC, Ng LT, and Lin CC: Anti-Herpes simplex virus activity of Bidens pilosa and Houttuynia cordata. Am J Chin Med 31: 355-362, 2003. 20. Lee JS, Kim IS, Kim JH, Kim JS, Kim DH, and Yun CY: Suppressive effects of Houttuynia cordata Thunb (Saururaceae) extract on Th2 immune response. J Ethnopharmacol 117: 34-40, 2008. 21. Dexter DL, Kowalski HM, Blazar BA, Fligiel Z, Vogel R, and Heppner GH: Heterogeneity of tumor cells from a single mouse mammary tumor. Cancer Res. 38: 3174–3181, 1978. 22. Heppner GH, Dexter DL, DeNucci T, Miller FR, and Calabresi P: Heterogeneity in drug sensitivity among tumor cell subpopulations of a single mammary tumor. Cancer Res. 38:3758–3763, 1978. 23. Heppner GH, Miller FR, and Shekhar PM: Non-transgenic models of breast cancer. Breast Cancer Res. 2: 331–334, 2000. 24. Morecki S, Yacovlev L,and Slavin S: Effect of indomethacin on tumorigenicity and immunity induction in a murine model of mammary carcinoma. Int. J. Cancer 75: 894–899, 1998. 25. Pulaski BA, Clements VK, Pipeling MR, and Ostrand-Rosenberg S: Immunotherapy with vaccines combining MHC class II ⁄ CD80+ tumor cells with interleukin-12 reduces established metastatic disease and stimulates immune effectors and monokine induced by interferon gamma. Cancer Immunol.Immunother. 49:34–45, 2000. 26. Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF, and Jones LW: Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol. 17:16-23, 1979. 27. ATCC (American Type Culture Collection) http://www.lgcstandards-atcc.org/LGCAdvancedCatalogueSearch/ProductDescription/tabid/1068/Default.aspx?ATCCNum=CRL-1435&Template=cellBiology 28. Ghosh A, Wang X, Klein E, and Heston WD: Novel role of prostate-specific membrane antigen in suppressing prostate cancer invasiveness. Cancer Res. 65:727-731, 2005. 29. Alimirah F, Chen J, Basrawala Z, Xin H, and Choubey D: PC-3 cell line expresses androgen receptor: implications for the androgen receptor functions and regulation. FEBS Lett. 580: 2294–2300, 2006. 30. Pulukuri SM, Gondi CS, Lakka SS, Julta A, Estes N, Gujrati M, and Rao JS: RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo. J. Biol. Chem. 280: 36529–36540, 2005. 31. Li GZ, Chai OH, Lee MS, Han EH, Kim HT, and Song CH: Inhibitory effects of Houttuynia cordata water extracts on anaphylactic reaction and mast cell activation. Biol Pharm Bull 28: 1864-1868, 2005. 32. Chang JS, Chiang LC, Chen CC, Liu LT, Wang KC, and Lin CC: Antileukemic activity of Bidens pilosa L. var. minor (Blume) Sherff and Houttuynia cordata Thunb. Am J Chin Med 29:303-312, 2001. 33. Hayashi K, Kamiya M, and Hayashi T: Virucidal effects of the steam distillate from Houttuynia cordata and its components on HSV-1, influenza virus, and HIV. Planta Med 61: 237-241,1995. 34. Chen YY, Liu JF, Chen CM, Chao PY, and Chang TJ: A study of the antioxidative and antimutagenic effects of Houttuynia cordata Thunb. using an oxidized frying oil-fed model. J Nutr Sci Vitaminol (Tokyo) 49: 327-333, 2003. 35. Flis S and Splwinski J: Inhibitory effects of 5-fluorouracil and oxaliplatin on human colorectal cancer cell survival are synergistically enhanced by sulindac sulfide. Anticancer Res 29:435-441, 2009. 36. Parmar VS, Jain SC, Bisht KS, Jain R, Taneja P, Jha A, Tyagi OD, Prasad AK, Wengel J, Olsen CE, and Boll PM: Phytochemistry of the genus Piper. Phytochemistry 46: 597–673, 1997. 37. Chen C, Chen H, Shiao M, Lin Y, Kuo Y, and Ou J: Inhibition of low density lipoprotein oxidation by tetrahydrofurofuran lignans from Forsythia suspensa and Magnolia coco. Planta Med. 65: 709–711, 1999. 38. Ju Y, Still CC, Sacalis JN, Li J, and Ho C-T: Cytotoxic coumarins and lignans from extracts of the northern prickly ash (Zanthoxylum americanum). Phytother. Res. 15: 441–443, 2001. 39. Meselhy MR: Constituents from Moghat, the roots of Glossostemon bruguieri (desf.). Molecules 8: 614–621, 2003. 40. Wang C-C, Chen S, and Wu T-S: The facile reversed-phase HPLC resolution of tetrahydrofurofuran nucleus lignans in traditional Chinese medicine: Quantitative analysis of asarinin and sesamin in Asari radix. J. Chin. Chem. Soc. 50: 261–266, 2003. 41. Jiao Y, Davin LB, and Lewis NG: Furanofuran lignan metabolism as a function of seed maturation in Sesamum indicum: Methylenedioxy bridge formation: In honour of Professor G. H. Neil Towers’ 75th birthday. Phytochemistry 49: 387–394, 1998. 42. Shyu, Y-S and Hwang, LS: Antioxidative activity of the crude extract of lignan glycosides from unroasted Burma black sesame meal. Food Res. Int. 35: 357–365, 2002. 43. Shimizu S, Akimoto K, Shinmen Y, Sugano M, and Yamada H: Sesamin is a potent and specific inhibitor of D5 desaturase in polyunsaturated fatty acid biosynthesis. Lipids 26: 512–516, 1991. 44. Chatrattanakunchai S, Fraser T, and Stobart K: Sesamin inhibits lysophosphatidylcholine acyltransferase in Mortierella alpina. Biochem. Soc. Trans. 28: 718–721, 2000. 45. Utsunomiya T, Chavali SR, Zhong WW , and Forse RA: Effects of sesamin-supplemented dietary fat emulsions on the ex vivo production of lipopolysaccharide-induced prostanoids and tumor necrosis factor {alpha} in rats. Am. J. Clin. Nutr. 72: 804–808, 2000. 46. Hirata F, Fujita K, Ishikura Y, Hosoda K, Ishikawa T, and Nakamura H: Hypocholesterolemic effect of sesame lignan in humans. Atherosclerosis 122: 135–136, 1996. 47. Kita S, Matsumura Y, Morimoto S, Akimoto K, Furuya M, Oka N, and Tanaka T: Antihypertensive effect of sesamin. II. Protection against two-kidney, one-clip renal hypertension and cardiovascular hypertrophy. Biol. Pharm. Bull. 18: 1283–1285, 1995. 48. Nakano D, Itoh C, Takaoka M, Kiso Y, Tanaka T, and Matsumura Y: Antihypertensive effect of sesamin. IV. Inhibition of vascular superoxide production by sesamin. Biol. Pharm. Bull. 25: 1247–1249, 2002. 49. Matsumura Y, Kita S, Morimoto S, Akimoto K, Furuya M, Oka N, and Tanaka T: Antihypertensive eddect of sesamin. I. Protection against deoxycorticosterone acetate salt-induced hypertension and cardiovascular hypertrophy. Biol. Pharm. Bull. 18: 1016–1019, 1995. 50. Matsumura Y, Kita S, Tanida Y, Taguchi Y, Morimoto S, Akimoto K, and Tanaka T: Antihypertensive effect of sesamin. III. Protection against development and maintenance of hypertension in stroke-prone spontaneously hypertensive rats. Biol. Pharm. Bull. 21: 469–473, 1998. 51. Akimoto K, Kitagawa Y, Akamatsu T, Hirose N, Sugano M, Shimizu S, and Yamada H: Protective effects of sesamin against liver damage caused by alcohol or carbon tetrachloride in rodents. Ann. Nutr. Metab. 37: 218–224, 1993. 52. Yamashita K, Kagaya M, Higuti N, and Kiso, Y: Sesamin and α-tocopherol synergistically suppress lipid-peroxide in rats fed with a high docosahexaenoic acid diet. Biofactors 11: 11–13, 2000. 53. Kamal-Eldin A, Pettersson D, and Appelqvist LA: Sesamin (a compound from sesame oil) increases tocopherol levels in rats fed ad libitum. Lipids 30: 499–505, 1995. 54. Hirose N, Doi F, Ueki T, Akazawa K, Chijiiwa K, Sugano M, Akimoto K, Shimizu S, and Yamada H: Suppressive effect of sesamin against 7,12-dimethylbenz[a]-anthracene induced rat mammary carcinogenesis. Anticancer Res. 12: 1259–1265, 1992. 55. Nakai M, Harada M, Nakahara K, Akimoto K, Shibata H, Miki W, and Kiso Y: Novel antioxidative metabolites in rat liver with ingested sesamin. J. Agric. Food Chem. 51: 1666–1670, 2003. 56. Borriello SP, Setchell KDR, Axelson M, and Lawson AM: Production and metabolism of lignans by the human faecal flora. J. Appl. Bacteriol. 58: 37–43, 1995. 57. Heinonen S, Nurmi T, Liukkonen K, Poutanen K, Wahala‥ K, Deyama T, Nishibe S, and Adlercreutz H: In vitro metabolism of plant lignans: New precursors of mammalian lignans enterolactone and enterodiol. J.Agric. Food Chem. 49: 3178–3186, 2001. 58. Saarinen NM, Warri A, Makela, SI, Eckerman C, Reunanen M, Ahotupa M, Salmi SM, Franke AA, Kangas L, and Santti R: Hydroxymatairesinol, a novel enterolactone precursor with antitumor properties from coniferous tree (Picea abies). Nutr. Cancer 36: 207–216, 2000. 59. Adlercreutz H, Fotsis T, Heikkinen R, Dwyer JT, Woods M, Goldin B R, and Gorbach SL: Excretion of the lignans enterolactone and enterodiol and of equol in omnivorous and vegetarian women and in women with breast cancer. Lancet 2: 1295–1299, 1982. 60. Ingram D, Sanders K, Kolybaba M, and Lopez D: Case-control study of phyto-oestrogens and breast cancer. Lancet 350: 990–994, 1997. 61. Vanharanta M, Voutilainen S, Lakka TA, van der Lee M, Adlercreutz H, and Salonen JT: Risk of acute coronary events according to serum concentrations of enterolactone: a prospective population-based case-control study. Lancet 354: 2112–2115, 1999. 62. Pietinen P, Stumpf K, Mannisto S, Kataja V, Uusitupa M, and Adlercreutz H: Serum enterolactone and risk of breast cancer: a casecontrol study in Eastern Finland. Cancer Epidemiol. Biomark. Prev. 10: 339–344, 2001. 63. Vanharanta M, Voutilainen S, Rissanen TH, Adlercreutz H, and Salonen JT: Risk of cardiovascular disease-related and all-cause death according to serum concentrations of enterolactone: Kuopio Ischaemic Heart Disease Risk Factor Study. Arch. Int. Med. 163: 1099–1104, 2003. 64. Penalvo JL, Heinonen SM, Aura AM, and Adlercreutz H: Dietary sesamin is converted to enterolactone in humans. J. Nutr. 134: 120–127, 2005. 65. Tsai CH, Lin FM ,Yang YC, Lee MT, Cha TL ,Wu GJ, Hsieh SC, and Hsiao PW: Herbal extract of Wedelia chinensis attenuates androgen receptor activity and orthotopic growth of prostate cancer in nude mice. Clin Cancer Res 15:5435-5444, 2009. 66. Jong TT and Jean MY: Constituents of Houttuyniae cordata and the crystal structure of vomifoliol. J. Chin. Chem. Soc. 40:399-402, 1993. 67. Lin FM, Chen LR, Lin EH, Ke FC, Chen HY, Tsai MJ, and Hsiao PW: Compounds from Wedelia chinensis synergistically suppress androgen activity and growth in prostate cancer cells. Carcinogenesis 28:2521-2529, 2007. 68. Deryugina EI and Quigley JP: Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev 25: 9–34, 2006. 69. Friedl P and Alexander S: Cancer invasion and the microenvironment: plasticity and reciprocity. Cell 147: 992–1009, 2011. 70. Hojilla CV, Wood GA, and Khokha R: Inflammation and breast cancer: metalloproteinases as common effectors of inflammation and extracellular matrix breakdown in breast cancer. Breast Cancer Res. 10: 205, 2008. 71. Hua H, Li M, Luo T, Yin Y, and Jiang Y: Matrix metalloproteinases in tumorigenesis: an evolving paradigm. Cell. Mol. Life Sci. 68: 3853–3868, 2011. 72. Gupta GP and Massague J: Cancer metastasis: building a framework. Cell 127: 679–695, 2006. 73. Steeg PS: Tumor metastasis: mechanistic insights and clinical challenges. Nat Med 12: 895–904, 2006. 74. Smith SC and Theodorescu D: Learning therapeutic lessons from metastasis suppressor proteins. Nat Rev Cancer 9:253–264, 2009. 75. Nagrath S, Sequist LV, Maheswaran S, Bell DW, Irimia D, Ulkus L, Smith MR, Kwak EL, Digumarthy S, and Muzikansky A: Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 450: 1235–1239, 2007. 76. Pantel K, Brakenhoff RH, and Brandt B: Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat Rev Cancer 8: 329–340, 2008. 77. Valastyan S and Weinberg RA: Tumor metastasis: molecular insights and evolving paradigms. Cell 146: 275-292, 2011. 78. Johnson GR, Whitehead R, Nicola NA: Effects of a murine mammary tumor on in vivo and in vitro hemopoiesis. Int. J. Cell Cloning 3: 91–105, 1985. 79. Serafini P, De Santo C, Marigo I, Cingarlini S, Dolcetti L, Gallina G, Zanovello P, and Bronte V: Derangement of immune responses by myeloid suppressor cells. Cancer Immunol. Immunother. 53: 64–72, 2004. 80. DuPre' SA and Hunter KW Jr.: Murine mammary carcinoma 4T1 induces a leukemoid reaction with splenomegaly: association with tumor-derived growth factors. Exp Mol Pathol. 82: 12-24, 2007. 81. Huggins C: Endocrine-induced regression of cancers. Cancer Res. 27:1925–1930 , 1967. 82. Beatson GT: Treatment of Cancer by Oophorectomy. Br. Med. J. 2: 1195, 1926. 83. Peinado H, Rafii S, and Lyden D: Inflammation joins the ‘‘niche’’. Cancer cell 14: 347-349, 2008. 84. Culig Z: Role of the androgen receptor axis in prostate cancer. Urology 62:21–26, 2003. 85. Heinlein CA and Chang C: Androgen receptor in prostate cancer. Endocr Rev 25:276–308, 2004. 86. Welch DR, Schissel DJ, Howrey RP, and Aeed PA: Tumor-elicited polymorphonuclear cells, in contrast to “normal” circulating polymorphonuclear cells, stimulate invasive and metastatic potentials of rat mammary adenocarcinoma cells. Proc. Natl. Acad. Sci. U. S. A. 86:5859–5863, 1989. 87. Wu QD, Wang JH, Condron C, Bouchier-Hayes D, Redmond HP: Human neutrophils facilitate tumor cell transendothelial migration. Am. J. Physiol.: Cell Physiol. 280:C814–C822, 2001. 88. Tabuchi T, Soma T, Yonekawa M, Komai T, Hashimoto T, and Adachi A: Reduction of VX2 transplanted tumor by granulocyte depletion using extracorporeal circulation on rabbit models. Anticancer Res. 12:795–798, 1992. 89. Pekarek LA, Starr BA, Toledano AY, and Schreiber H: Inhibition of tumor growth by elimination of granulocytes. J. Exp. Med. 181:435–440, 1995. 90. Bronte V, Wang M, Overwijk WW, Surman DR, Pericle F, Rosenberg SA, and Restifo NP: Apoptotic death of CD8+ T lymphocytes after immunization: induction of a suppressive population of Mac-1+/Gr-1+ cells. J. Immunol. 161:5313–5320, 1998. 91. Kusmartsev S and Gabrilovich DI: Immature myeloid cells and cancer-associated immune suppression. Cancer Immunol. Immunother. 51: 293–298, 2002. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/15577 | - |
dc.description.abstract | 慢性發炎可促發許多不同種類的癌症生長。因此,減緩發炎成為抗癌治療上的重要契機。多篇報導指出中草藥之一的HC 植物,具備抗發炎、抗病毒、抗細菌及抗白血病的生物特性。然而,利用HC治療其他癌症的發生鮮少有文獻提及。本篇論文中,我們同時在細胞層次及動物活體內研究該草藥在治療乳癌及前列腺癌的效果。藉由以水及甲醇為移動相建立的矽膠管柱層析法,我們將HC酒精粗萃物分為16個區段分別收集。由本實驗室先前建立的報導基因細胞模式發現,其中的區段6,7,8號可在前列腺癌細胞中,調控受雄性素接受器控制前列腺特異性抗原之下游報導基因的轉錄作用,而且該調控效果亦會隨著藥物劑量增加而愈趨明顯;進一步由化學鑑定方式,確定F7-3正是7號區段中主要的活性成份。我們利用噬菌斑減少分析法發現區段8及9號可抑制流行性感冒病毒的複製,而10號區段也具備些微的抑制效果。即便在100 μg/ml的濃度,分別以6, 7, 8, 9, 10號區段給予不同種類的乳癌及前列腺癌細胞處理24小時,仍無法顯著地降低癌細胞的存活率,但8號區段卻能有效地抑制這些癌細胞的侵犯能力。本實驗室亦利用實驗動物原位植入小鼠同源乳癌及異源前列腺癌細胞的活體模式分析HC酒精萃取物之配方的藥效。該草藥萃取物可減緩原位癌的生長、抑制癌細胞體內轉移,且未有明顯的毒性。利用此一臨床前實驗研究法證明,HC可作為化學治療或輔助療法上的選擇。 | zh_TW |
dc.description.abstract | Chronic inflammation can augment tumor development in various types of cancers. Reduction of inflammation, is therefore, an important anticancer therapeutic opportunity. It is reported that HC, a traditional Chinese herbal medicine, has many biological properties such as anti- inflammation, antiviral, antibacterial and anti-leukemic activities. The application of this herb to other cancers, however, is rarely proposed. In this study, we applied this herbal drug to breast and prostate cancers both in vitro and in vivo. The HC ethanolic crude extract was fractionated by silica gel column chromatography using a H2O and EtOH developing system, resulting in the collection of HC fractions 1~16. We found that HC ethanolic extract fractions 6,7, and 8 could modulate the androgen receptor (AR) activation of transcription from prostate-specific antigen (PSA) promoter within prostate cancer cells in a dose-dependent manner and further identified F7-3 within F7 was the major constituent that contributed to its activity. We also found that HC F8 and F9 could inhibit replication of influenza virus via plaque reduction assay (data not shown). F10 also had very slight effect of this (data not shown). Even though treatment with HC F6, 7, 8, 9, and 10 separately at concentrations below 100 ug/ml for 24 hours showed no significant decrease in the survival rate of either types of prostate cancer cell lines, HC F8 could inhibit the invasiveness of these cancer cells efficiently. The in vivo efficacy of oral administration of a standardized extract of HC were analyzed in animals bearing orthotopic breast cancer allograft and prostate cancer xenograft transplants. The herbal extract retarded the tumor growth without observable toxicity. This preclinical study thus provides strong evidence that HC is a good candidate for chemoprevention or complementary medicine. | en |
dc.description.provenance | Made available in DSpace on 2021-06-07T17:48:11Z (GMT). No. of bitstreams: 1 ntu-102-R98b42016-1.pdf: 5736833 bytes, checksum: c0cbcad1506f94f85a835c8eb2d0424e (MD5) Previous issue date: 2013 | en |
dc.description.tableofcontents | 口試委員會審定書........................................................................................................i
中文摘要...........................................................ii Abstract .........................................................iii Introduction .......................................................1 Materials and methods Plant materials, cells, and reagents..................................5 Plant extracts preparation...........................................5 Compound isolation and identification................................5 Luciferase assays...................................................6 Cell invasion assay..................................................7 Cell viability analysis..............................................7 In vivo study........................................................7 Histopathological staining and Immunohistochemistry................................................8 Statistical analysis................................................8 Results I. Determination of the chemical fingerprinting of crude HC ethanolic extract and its fraction 7 (F7) and identification of major bioactive compound within F7..................................................10 II. F6, F7 , and F8 of the crude HC ethanolic extract suppress androgen-induced PSA expression.....................................10 III.Combination of bioactive HC fragments synergistically increase the anti-proliferative effect both in androgen-dependent and independent PCa cells..............................................................11 IV.HC ethanolic extract F8 suppresses breast and prostate cancer invasion...........................................................12 V.HC ethanolic extract F8~10 mixed formula suppresses 4T1 mammary tumor growth in allograft mouse model......................................14 VI. HC ethanolic extract F8~10 mixed formula diminishes lung metastatic burden of breast cancer.............................................15 VII.HC ethanolic extract F7~9 mixed formula inhibits the tumor growth and reduces lung metastatic burden in breast cancer allograft model..16 VIII.HC ethnolic extract F7~9 formula could relieve splenomegaly, a paraneoplastic syndrome often observed in 4T1-bearing mice............18 IX.HC ethanolic extract F7~9 formula suppresses PC-3 prostatic tumor growth and metastasis in xenograft mouse model........................18 Discussion.........................................................20 References.........................................................24 Figure legends..................................................... 34 | |
dc.language.iso | en | |
dc.title | HC植物萃取物對於乳癌及前列腺癌潛在抗癌效應 | zh_TW |
dc.title | Potential anti-tumor effect of HC plant extract on breast and prostate cancer | en |
dc.type | Thesis | |
dc.date.schoolyear | 101-2 | |
dc.description.degree | 碩士 | |
dc.contributor.coadvisor | 鄭石通 | |
dc.contributor.oralexamcommittee | 李明學 | |
dc.subject.keyword | HC植物,抗發炎,原位同源及異源性移植,乳癌,前列腺癌, | zh_TW |
dc.subject.keyword | HC,anti-inflammation,orthotopic allograft and xenograft transplants,breast cancer,prostate cancer, | en |
dc.relation.page | 71 | |
dc.rights.note | 未授權 | |
dc.date.accepted | 2013-04-02 | |
dc.contributor.author-college | 生命科學院 | zh_TW |
dc.contributor.author-dept | 植物科學研究所 | zh_TW |
顯示於系所單位: | 植物科學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-102-1.pdf 目前未授權公開取用 | 5.6 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。